On March 12, 2026, Ultragenyx Pharmaceutical Inc. announced positive Phase 3 results for DTX301, showing an 18% reduction in plasma ammonia levels in treated patients. The study indicates significant clinical benefits for patients with OTC deficiency, maintaining normal ammonia levels.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.